日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial

接受瑞博西尼联合非甾体类芳香化酶抑制剂治疗的 HR+/HER2- 早期乳腺癌患者的健康相关生活质量：NATALEE 试验结果

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-1724
Fasching, Peter A; Slamon, Dennis; Nowecki, Zbigniew; Kukielka-Budny, Bozena; Stroyakovskiy, Daniil; Yardley, Denise A; Huang, Chiun-Sheng; Chan, Arlene; Chia, Stephen; Martín, Miguel; Rugo, Hope S; Loi, Sherene; Hurvitz, Sara; Untch, Michael; Afenjar, Karen; Fresco, Rodrigo; Danyliv, Andriy; Ferrusi, Ilia; Li, Zheng; Hortobagyi, Gabriel
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer

在真实世界人群中，对HR+/HER2-早期乳腺癌患者的侵袭性疾病无进展生存期和总生存期进行相关性分析

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.35817
Graff, Stephanie L; Tolaney, Sara M; Hart, Lowell L; Razavi, Pedram; Janni, Wolfgang; Schwartzberg, Lee S; Danyliv, Andriy; Akdere, Murat; Ferrusi, Ilia; Adhikary, Rishi Rajat; O'Shaughnessy, Joyce A
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer

在激素受体阳性/HER2阴性早期乳腺癌中，瑞博西尼+非甾体类芳香化酶抑制剂与阿贝西利+内分泌治疗的匹配调整间接比较

期刊:Journal of Comparative Effectiveness Research
影响因子:2.5
doi:10.57264/cer-2025-0082
Chia, Stephen; Li, Jie; Ma, Fei; Stellato, Daniel; Danyliv, Andriy; Ferrusi, Ilia; Hu, Huilin; Akdere, Murat; Makris, Andreas
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2025
文献求助 收藏

Economic evaluation of targeted cancer interventions: critical review and recommendations

针对癌症干预措施的经济评价：批判性回顾和建议

期刊:Genetics in Medicine
影响因子:6.2
doi:10.1097/GIM.0b013e31821f3e64
Elkin, Elena B; Marshall, Deborah A; Kulin, Nathalie A; Ferrusi, Ilia L; Hassett, Michael J; Ladabaum, Uri; Phillips, Kathryn A
肿瘤
肿瘤免疫
发表日期：2011
文献求助 收藏

Do economic evaluations of targeted therapy provide support for decision makers?

靶向治疗的经济评价能否为决策者提供支持？

期刊:Journal of Oncology Practice
影响因子:
doi:10.1200/JOP.2011.000315
Ferrusi, Ilia L; Leighl, Natasha B; Kulin, Nathalie A; Marshall, Deborah A
发表日期：2011
文献求助 收藏

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients

乳腺癌患者人表皮生长因子受体2检测策略的临床实践模式和成本效益

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.24574
Phillips, Kathryn A; Marshall, Deborah A; Haas, Jennifer S; Elkin, Elena B; Liang, Su-Ying; Hassett, Michael J; Ferrusi, Ilia; Brock, Jane E; Van Bebber, Stephanie L
信号转导
肿瘤
肿瘤免疫
乳腺癌
发表日期：2009
文献求助 收藏

Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses

回顾曲妥珠单抗治疗10年：HER2检测的作用是什么？一项关于卫生经济学分析的系统性综述

期刊:Personalized Medicine
影响因子:1.8
doi:10.2217/17410541.6.2.193
Ferrusi, Ilia L; Marshall, Deborah A; Kulin, Nathalie A; Leighl, Natasha B; Phillips, Kathryn A
HER2
发表日期：2009
文献求助 收藏